NYSE American - Delayed Quote USD

Scorpius Holdings, Inc. (SCPX)

0.0768 -0.1047 (-57.69%)
At close: May 14 at 4:00 PM EDT
0.0786 +0.00 (+2.34%)
Pre-Market: 4:57 AM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
6,994.8380
6,994.8380
370.1760
--
2,947.9690
Cost of Revenue
2,736.9980
2,736.9980
81.2950
--
--
Gross Profit
4,257.8400
4,257.8400
288.8810
--
--
Operating Expense
46,290.0120
46,290.0120
40,354.0410
31,170.7010
27,873.3310
Operating Income
-42,032.1720
-42,032.1720
-40,065.1600
-31,170.7010
-24,925.3620
Net Non Operating Interest Income Expense
-319.6490
-319.6490
804.7380
815.3160
566.7180
Other Income Expense
18.2220
18.2220
-2,330.5820
-5,191.3960
-2,022.7450
Pretax Income
-42,333.5990
-42,333.5990
-41,591.0040
-35,546.7810
-26,381.3890
Tax Provision
-571.1200
-571.1200
-215.9370
-145.9740
--
Net Income Common Stockholders
-45,217.1680
-45,217.1680
-43,434.7060
-35,071.4680
-26,049.7370
Diluted NI Available to Com Stockholders
-45,217.1680
-45,217.1680
-43,434.7060
-35,071.4680
-26,049.7370
Basic EPS
-1.74
-1.74
-1.70
-1.41
-1.63
Diluted EPS
-1.74
-1.74
-1.70
-1.41
-1.63
Basic Average Shares
26,046.5940
26,046.5940
25,606.3260
24,913.9420
15,982.5680
Diluted Average Shares
26,046.5940
26,046.5940
25,606.3260
24,913.9420
15,982.5680
Total Operating Income as Reported
-42,032.1720
-42,032.1720
-40,222.6450
-35,419.0390
-26,124.3620
Total Expenses
49,027.0100
49,027.0100
40,435.3360
31,170.7010
27,873.3310
Net Income from Continuing & Discontinued Operation
-45,217.1680
-45,217.1680
-43,434.7060
-35,071.4680
-26,049.7370
Normalized Income
-40,267.8450
-40,267.8450
-39,109.2771
-30,024.1624
-23,838.5700
Interest Income
457.1890
457.1890
987.2470
815.3160
566.7180
Interest Expense
776.8380
776.8380
182.5090
--
--
Net Interest Income
-319.6490
-319.6490
804.7380
815.3160
566.7180
EBIT
-41,556.7610
-41,556.7610
-41,408.4950
-31,170.7010
-24,925.3620
EBITDA
-33,991.2550
-33,991.2550
-38,262.8550
-30,563.0340
-24,592.2100
Reconciled Cost of Revenue
2,736.9980
2,736.9980
81.2950
--
--
Reconciled Depreciation
7,565.5060
7,565.5060
3,145.6400
607.6670
333.1520
Net Income from Continuing Operation Net Minority Interest
-40,146.4610
-40,146.4610
-40,947.5760
-35,071.4680
-26,049.7370
Total Unusual Items Excluding Goodwill
123.0440
123.0440
-1,847.8930
-5,068.1180
-2,211.1670
Total Unusual Items
123.0440
123.0440
-1,847.8930
-5,068.1180
-2,211.1670
Normalized EBITDA
-34,114.2990
-34,114.2990
-36,414.9620
-25,494.9160
-22,381.0430
Tax Rate for Calcs
0.0000
0.0000
0.0000
0.0000
--
Tax Effect of Unusual Items
1.6600
1.6600
-9.5941
-20.8124
--
12/31/2020 - 7/24/2013

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

TOVX Theriva Biologics, Inc.
0.3740
-0.03%
 
SLRX Salarius Pharmaceuticals, Inc.
0.4551
-3.97%
 
TRAW Traws Pharma, Inc.
0.6501
+0.70%
 
QLGN Qualigen Therapeutics, Inc.
0.2880
+8.68%
 
AZTR Azitra, Inc.
0.1759
-6.44%
 
VCNX Vaccinex, Inc.
5.51
-0.36%
 
TNXP Tonix Pharmaceuticals Holding Corp.
0.1800
+5.20%
 
INM InMed Pharmaceuticals Inc.
0.2670
+1.44%
 
GOVX GeoVax Labs, Inc.
1.7000
+3.03%
 
NLSP NLS Pharmaceutics Ltd.
0.1509
+7.40%